A Transient Proteinuria: An Unusual Complication of Hypothyroidism

R. Hajji^1, , F. Derbali¹, K. Mnafgui², S. Zribi¹, M. Elleuch¹, N. Kammoun¹ and Z. Jallali³

¹Internal Medicine Department, Sidi Bouzid Regional Hospital, Sidi Bouzid, Tunisia

²Pathophysiology Laboratory, FSS, Tunisia

³Nephrology Department, Sidi Bouzid Regional Hospital, Sidi Bouzid, Tunisia

Cite this paper

R. Hajji, F. Derbali, K. Mnafgui, S. Zribi, M. Elleuch, N. Kammoun and Z. Jallali. A Transient Proteinuria: An Unusual Complication of Hypothyroidism. American Journal of Medical Case Reports. 2014; 2(11):237-239. doi: 10.12691/AJMCR-2-11-3

Abstract

Background: Although the effect of thyroid hormones is very important on renal function and glomerular filtration rate, it is often overlooked. Hypothyroidism is sometimes accompanied by a decrease in the glomerular filtration rate and hyponatremia. Observation: A33-year-old man was admitted in intensive care unit for an inaugural diabetic ketoacidosis in December 2012. He has been diagnosed as hypothyroidism case since 2005. He had a replacement therapy that he had given up in 2011. On The physical examination he exhibited a general fatigue with fever and sweats. He suffered from myalgia and proximal muscle weakness, edema of renal type and a few crackles. The biology showed ketoacidosis, progressive acute renal failure of deterioration associated with important rhabdomyolysis and proteinuria of 5.7 g/24 h. Normal eye fundus was able to rule out diabetic nephropathy. In addition to the treatment of ketoacidosis, lung disease and the fluid overload, hormone replacement therapy was reinstituted. The evolution was marked bythe disappearance of edema, fever, rhabdomyolysis and proteinuria. Discussion: The rhabdomyolysis, secondary to hypothyroidism, is atthe origin of renal failure. In this case, proteinuria is exceptional. Themajor part of the renal manifestations during thyroid dysfunctions isreversible with hormone therapy. Conclusion: Transient proteinuria isexceptional in hypothyroidism. It is another face of kidney involvementin thyroid disorders.

Keywords

hypothyroidism, proteinuria, kidney

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Kaptein EM. Thyroid function in renal failure. ContribNephrol 1986; 50:64-72.
[2]	Basu G1, Mohapatra A. Interactions between thyroid disorders and kidney disease. Indian J EndocrinolMetab. 2012; 16(2): 204-13.
[3]	Iglesias P1, Díez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol. 2009; 160 (4): 503-15.
[4]	Dousdampanis P, Trigka K, Vagenakis GA, Fourtounas C. The thyroid and the kidney: a complex interplay in health and disease. Int J Artif Organs 2014; 37(1): 1-12.
[5]	Crowley WF Jr, Ridgway EC, Bough EW, Francis GS, Daniels GH, Kourides IA, et al. Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med 1977; 296: 1-6.
[6]	Diekman MJ, Harms MP, Endert E, Wieling W, Wiersinga WM. Endocrine factors related to changes in total peripheral vascular resistance after treatment of thyrotoxic and hypothyroid patients. Eur J Endocrinol 2001; 144: 339-46.
[7]	Singer MA. Of mice and men and elephants: Metabolicrate sets glomerular filtration rate. Am J Kidney Dis 2001; 37(1):164-78.
[8]	Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-9.
[9]	Schmid C, Brandle M, Zwimpfer C, Zapf J, Wiesli P. Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor. Clin Chem. 2004; 50(1): 228-31.
[10]	Klanke B, Simon M, Rockl W, Weich HA, Stolte H, Grone HJ. Effects of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permselectivity of the isolated perfused rat kidney.Nephrol Dial Transplant 1998; 13: 875-85.
[11]	Fukumura D, Gohongi T, Kadambi A,Izumi Y, Ang J, Yun CO, et al.Predominant role of endothelial nitric oxide synthase in vascular endothelialgrowth factor-induced angiogenesis and vascular permeability.ProcNatlAcadSci U S A. 2001; 98(5): 2604-9.
[12]	Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J BiolChem 1998; 273: 30336-43.
[13]	Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J BiolChem 1999; 274: 33057-63.
[14]	Guler HP, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. ProcNatlAcadSci U S A. 1989; 86(8): 2868-72.
[15]	Guler HP, Eckardt KU, Zapf J, Bauer C, Froesch ER. Insulin-like growth factor I increase glomerular filtration rate and renal plasma flow in man. ActaEndocrinol (Copenh). 1989; 121(1): 101-6.
[16]	Bradley SE, Coelho JB, Sealey JE, Edwards KD, Stephan F. Changes in glomerulotubular dimensions, single nephron glomerular filtration rates and the renin angiotensin system in hypothyroid rats. Life Sci. 1982; 30(7-8): 633-9.
[17]	Montenegro J, Gonzalez O, Saracho R, Aguirre R, Martinez I. Changes in renal function in primary hypothyroidism. Am J Kidney Dis. 1996; 27(2): 195-8.
[18]	Hanna FW., Scanlon MF., Hyponatraemia, hypothyroidism, and role of arginine-vasopressin. Lancet. 1997; 350(9080): 755-6.
[19]	Wheatley T, Edwards OM. Mild hypothyroidism and oedema: Evidence for increased capillary permeability to protein. ClinEndocrinol (Oxf). 1983; 18(6): 627-35.
[20]	Suher M., Koc E., Ata N., Ensari C., Relation of thyroid disfunction, thyroid autoantibodies, and renal function. Ren Fail. 2005; 27(6): 739-42.
[21]	Yen PM.Physiological and molecular basis of thyroid hormone action.PhysiolRev. 2001; 81(3): 1097-142.
[22]	Vargas F, Moreno JM, Rodriguez-Gomez I, Wangensteen R, Osuna A, Alvarez-Guerra M, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 2006; 154(2): 197-212.
[23]	Asmah BJ, Wan Nazaimoon WM, Norazmi K, Tan TT, Khalid BA. Plasma renin and aldosterone in thyroid diseases. HormMetab Res 1997; 29(11): 580-3.
[24]	Zimmerman RS, Ryan J, Edwards BS, Klee G, Zimmerman D, Scott N, et al. Cardiorenal endocrine dynamics during volume expansion in hypothyroid dogs. Am J Physiol. 1988; 255(1 Pt 2): R61-6.
[25]	Garg LC, Tisher CC. Effects of thyroid hormone on Na-K-adenosine triphosphatase activity along the rat nephron. J Lab Clin Med. 1985; 106(5): 568-72.
[26]	Marcos Morales M, PurchioBrucoli HC, Malnic G, Gil Lopes A. Role of thyroid hormones in renal tubule acidification. Mol Cell Biochem 1996; 154(1): 17-21.
[27]	Michael UF, Barenberg RL, Chavez R, Vaamonde CA, Papper S. Renal handling of sodium and water in the hypothyroid rat. Clearance and micropuncture studies. J Clin Invest 1972; 51(6): 1405-12.
[28]	Derubertis FR Jr, Michelis MF, Bloom ME, Mintz DH, Field JB, Davis BB. Impaired water excretion in myxedema. Am J Med 1971; 51(1): 41-53.
[29]	Spector DA., Davis PJ., Helderman JH., Bell B., Utiger RD., Thyroid function and metabolic state in chronic renal failure. Ann Intern Med. 1976; 85(6): 724-30.
[30]	Spaulding SW., Gregerman RI., Free thyroxine in serum by equilibrium dialysis: Effects of dilution, specific ions and inhibitors of binding. J ClinEndocrinolMetab. 1972; 34(6): 974-82.
[31]	Schmitz PH1, de Meijer PH, Meinders AE.. Hyponatremia due to hypothyroidism: a pure renal mechanism. Net J Med 2001; 58 (3): 143-9.
[32]	Sari R, Sevinc A. Life-threatening hyponatremia due to cessation of L-thyroxine. J Natl Med Assoc. 2003; 95(10): 991-4.
[33]	Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, deVisser M.Rhabdomyolysis: review of the literature.NeuromusculDisord. 2014; 24(8):651-9.
[34]	Kimmel M, Braun N, Alscher M. Influence of thyroid function on different kidney function tests. Kidney Blood Press Res 2012; 35(1): 9-17.